A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
Clinical trial NCT02435433 · COMPLETED
Trial details
- NCT number
- NCT02435433
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-07-20
- Primary completion
- 2018-03-15
- Enrollment
- 399
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.